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Introduction {#sec001}
============

Treatment-resistant depression (TRD) is often operationally defined as a major depressive episode that fails to remit after treatment with at least two antidepressants of different classes at therapeutic doses for an adequate treatment period \[[@pone.0226486.ref001]--[@pone.0226486.ref008]\]. More extensive staging criteria for TRD have been proposed as well \[[@pone.0226486.ref001]\]. TRD must be distinguished from inadequately treated depression resulting from numerous factors such as patient non-compliance, intolerance to side effects, misdiagnosis (e.g., thyroid disease), low dosage, etc. \[[@pone.0226486.ref002]\]. It is unclear if TRD is a particularly malignant form of depression with its own pathophysiology, or if treatment-related changes in brain metabolism are different than those found in treatment-responsive depression \[[@pone.0226486.ref003]\]. Patients with TRD are at increased risk of relapse \[[@pone.0226486.ref004]\]. Also, most TRD patients have numerous psychiatric comorbidities inherently raising potential confounds with diagnosis \[[@pone.0226486.ref005]--[@pone.0226486.ref008]\].

The STAR\*D trial documents TRD is a frequent occurrence and a serious problem in psychiatry afflicting about 30% of patients \[[@pone.0226486.ref004]\]. In terms of disease burden, it is second only to back pain in terms of life-years of disability \[[@pone.0226486.ref009]\]. The high significance of TRD has prompted an aggressive search for novel, more effective treatments including new classes of antidepressants (e.g., glutamatergic receptor antagonists, neuroactive steroids), add-on treatments (drug combinations, boosters such as lithium or liothyronine, atypical neuroleptics, mood stabilizers), and devices for neuromodulation (e.g., transcranial magnetic stimulation, TMS; vagus nerve stimulation, VNS; deep brain stimulation, DBS, direct current stimulation, DCS).

Despite the clinical importance of TRD, few studies have examined its biology and treatment. Several challenges have hindered such research. The recruitment of TRD patients is difficult. These patients are likely heterogenous in pathology, have numerous comorbidities, and are quite ill with significant risk for suicide. Their cross-sectional physiology may be confounded by the many previous treatment trials. At best, the medley of ineffective medications needs wash out, but this may lead to potential withdrawal symptoms or symptom worsening. Encouragement to undergo yet another treatment after so many failed trials becomes paramount. These patients need frequent follow-up and clinician availability. Despite these impediments, some work has been done using ^18^F-fluorodeoxyglucose positron emission tomography (FDG PET) in those with TRD \[[@pone.0226486.ref010]--[@pone.0226486.ref018]\]. However, not only does the biology of TRD, if homogeneous, remain unclear, but also no biomarkers predicting treatment resistance have reached clinical utility for this group of patients.

Past neuroimaging studies of treatment-responsive depression have highlighted the amygdala and subgenual anterior cingulate cortex (sgACC) as key nodes of depression-related circuity showing reduction in activity with successful treatment (see reviews \[[@pone.0226486.ref019]--[@pone.0226486.ref021]\]), although there are exceptions (e.g., no sg ACC change \[[@pone.0226486.ref022]\]; no amygdala change \[[@pone.0226486.ref023]\]). Studies have suggested several features may characterize TRD such as sgACC hyperactivity, amygdala hyperactivity, prefrontal/thalamic dysconnectivity, habenular connectivity, prefrontal hypoactivity, and hippocampal subfield volumes \[[@pone.0226486.ref010], [@pone.0226486.ref013], [@pone.0226486.ref014], [@pone.0226486.ref024]--[@pone.0226486.ref026]\]; however, consensus is yet to be achieved.

To our knowledge, there are no prior studies of brain metabolism in TRD patients with drug washout to establish a baseline examined both before and after a full trial of a combination antidepressant drug and atypical neuroleptic. Yet, the combination of antidepressant and atypical neuroleptic is being used increasingly throughout the world to treat TRD. The present study is of necessity preliminary, as no prior data existed with which to power the sample size or even to determine its feasibility.

The focus of this work rests on the amygdala and sgACC regions based on extensive prior literature. For example, unmedicated depressed patients have hypermetabolic amygdalae at rest \[[@pone.0226486.ref020]\]; decreased amygdala volume that correlates with depression severity \[[@pone.0226486.ref027], [@pone.0226486.ref028]\]; increased amygdala reactivity to sensory stimuli even without conscious awareness \[[@pone.0226486.ref029], [@pone.0226486.ref030]\]; amygdala reactivity prognostic of response to cognitive therapy \[[@pone.0226486.ref031]\]; sustained amygdala responses to negative words \[[@pone.0226486.ref032]\]; and disrupted functional connectivity\[[@pone.0226486.ref033]--[@pone.0226486.ref036]\].

The amygdala is densely connected both anatomically and functionally to the sgACC \[[@pone.0226486.ref037]--[@pone.0226486.ref039]\]. Depressed patients can show focal atrophy in the sgACC \[[@pone.0226486.ref021], [@pone.0226486.ref040]--[@pone.0226486.ref042]\]. Both hyperactivity and hypoactivity in the sgACC of depressed patients at rest have been reported \[[@pone.0226486.ref010], [@pone.0226486.ref021], [@pone.0226486.ref040]\]. Several antidepressant treatments decrease activity in the sgACC (e.g., SSRI, \[[@pone.0226486.ref023]\]; antidepressant placebo response \[[@pone.0226486.ref043]\]; DBS \[[@pone.0226486.ref010]\]; electroconvulsive therapy, ECT \[[@pone.0226486.ref044]\]; and VNS \[[@pone.0226486.ref017], [@pone.0226486.ref018]\]. DBS of tracts to the amygdala are neurosurgical targets for the treatment of refractory depression \[[@pone.0226486.ref045]\]. Greater efficacy of transcranial magnetic stimulation was associated with anticorrelated activity between the dorsolateral prefrontal cortex and sgACC \[[@pone.0226486.ref046]\]. Of note, healthy subjects' ratings of negative affectivity during the prior month correlated with activity in the sgACC \[[@pone.0226486.ref047]\].

Given these a priori targets, this cohort observational study sought to test feasibility and to characterize regional brain metabolism in TRD before and after adequate treatment with a combination of an atypical neuroleptic (olanzapine) and fluoxetine (O/F), a selective serotonin reuptake inhibitor (SSRI) antidepressant. Use of these drugs in combination will be referred to hereafter as O/F.

This drug combination was the first drug approved by the USA Food and Drug Administration in 2009 specifically for the indication of TRD \[[@pone.0226486.ref048]\]. There have been several clinical trials, reviews, and meta-analyses examining the efficacy of O/F for TRD; that discussion is beyond the scope of this study \[[@pone.0226486.ref049]--[@pone.0226486.ref056]\]. Originally, use of O/F was based on preclinical work. Neurobiological changes associated with O/F dosing in rats include increased prefrontal monoamine levels \[[@pone.0226486.ref057], [@pone.0226486.ref058]\] and suppression of limbic immediate-early gene expression \[[@pone.0226486.ref059]\] relative to olanzapine or fluoxetine alone. No differential effects on limbic neurogenesis were found using O/F, whereas the individual drugs are associated with neurogenesis \[[@pone.0226486.ref060]\]. Whereas higher doses of O/F increased levels of neurotrophin-3 selectively in rat prefrontal cortex, low O/F doses or higher doses of olanzapine or fluoxetine administered individually did not \[[@pone.0226486.ref061]\]. These animal findings suggest some unique effects of O/F therapy not accounted for by the actions of the individual drugs.

The aim of the present work was not to assess efficacy or health outcomes in a clinical trial, as this has been reported previously (see above). Rather, the project's purpose was to use imaging to bear on the question of mechanisms. Whether such combination treatments for TRD follow similar metabolic effects to other antidepressants in treatment-responsive depression is unknown. In addition, the individual TRD patient's deviation from a normative database indicate for the first time the potential changes in regional brain metabolism in an individual, unmedicated, TRD patient. Such data could address preliminarily whether sgACC hypermetabolism or other biomarker is characteristic of TRD, a key issue in patient selection for future treatment trials of TRD.

Materials and methods {#sec002}
=====================

Participants {#sec003}
------------

Twenty-five participants with severe TRD were enrolled. They had many psychotherapy and medication trials, some even failing convulsive therapy. They all had a longstanding chronic illness lasting many years. Most had comorbid psychiatric disorders. They were recruited and enrolled through referral from physicians' outpatient clinics known to specialize in the treatment of TRD (co-authors: DA, BR, FSA). The principal inclusion criterion was severe, refractory major unipolar depressive disorder (Scheduled Clinical Interview for Diagnostic and Statistical Manual-IV; SCID \[[@pone.0226486.ref062]\]) as the primary diagnosis. Exclusion criteria included a lifetime history of cognitive impairment, psychosis, bipolar disorder, drug dependence, pregnancy, as well as any clinically significant findings on magnetic resonance imaging. All subjects provided written informed consent as approved by the VA Institutional Review Board (IRB) and the Radioactive Drug Research Committee (RDRC) approved by the FDA.

Treatment {#sec004}
---------

Patients' polypharmacy was tapered with washout for two weeks before the baseline measurement of glucose uptake using FDG PET as described previously \[[@pone.0226486.ref063]\]. They were then titrated to the maximal tolerated dose of fluoxetine (≤ 60 mg) and olanzapine (≤ 30 mg). The use of the combination of an SSRI such as fluoxetine and an atypical neuroleptic such as olanzapine is a standard of care in the management of patients with TRD. The maximal tolerated dose was held constant for eight weeks except for rescue medication of low dose benzodiazepine or short acting hypnotics for severe anxiety or insomnia. Given the seriousness of the illness, risk for suicide, and focus on mechanisms rather than efficacy, the study had no placebo control medication. Patients were seen either weekly or every two weeks (depending on stability) during wash out and treatment. Compliance was checked by counting pills every 1--2 weeks. Side effects were evaluated with open-ended questions without checklists typical of clinical trials. After treatment with O/F for eight weeks and PET imaging, they were returned to their referring psychiatrist for continued assessment and follow-up.

Clinical assessments {#sec005}
--------------------

All subjects were assessed by their referring physician as having TRD as their primary diagnosis. Medical records were reviewed to ensure all subjects had at least two trials of antidepressants from different classes with adequate doses and duration of treatment (at least stage III TRD \[[@pone.0226486.ref001]\]). All subjects underwent structured diagnostic interviews using the SCID-1, Clinician Version \[[@pone.0226486.ref064]\]. The primary outcome measure was the change in Montgomery-Asberg Depression Rating Scale (MADRS \[[@pone.0226486.ref065]\]) score after eight weeks of treatment. The MADRS has good psychometric properties. The inter-rater reliability (concordance in score between a pair of independent raters) as measured by the intraclass correlation is 0.86 \[[@pone.0226486.ref066]\]. The internal consistency reliability (i.e., intra-observer reliability) using test/re-test method (clinical status between tests considered constant; i.e., stability over time) had an intraclass correlation of 0.78 \[[@pone.0226486.ref067]\]. As is standard for assessing responses to antidepressant interventions \[[@pone.0226486.ref068]\], a clinical response was defined a priori as a greater than or equal to 50% drop in depression score, while a remission was defined a priori as a MADRS of less than or equal to 8. Anxiety was scored with the Hamilton Anxiety Scale (HAMA \[[@pone.0226486.ref069]\]). Additional testing not directly pertinent to the present study included Clinical Global Impression Scale (CGI \[[@pone.0226486.ref070]\]), Mini-Mental Status Exam (MMSE \[[@pone.0226486.ref071]\]), Shipley Institute of Living Scale \[[@pone.0226486.ref072]\], Edinburgh Handedness Inventory \[[@pone.0226486.ref073]\], Profile of Mood States (POMS) \[[@pone.0226486.ref074]\], and Positive Affect Negative Affect Scale (PANAS \[[@pone.0226486.ref075]\]).

Positron emission tomography {#sec006}
----------------------------

Patients were scanned after washout (pre-treatment or baseline) and after completion of the eight weeks of treatment at maximal tolerated dose (post-treatment). Participants fasted for at least six hours before imaging; blood glucose was checked immediately before scanning. The relative regional glucose uptake was measured by injecting intravenously a bolus of ^18^F-FDG in saline at a dose of 185 MBq (5 mCi)/70 kg. They rested for 50 minutes during tracer uptake with eyes closed and ears open in a dimly lit, quiet room while being monitoring for wakefulness. The scanner was a Siemens (Knoxville, TN, USA) ECAT EXACT 47 operated in 2-D mode with septae extended. After measured attenuation, counts were collected during an emission scan lasting 20 minutes. Data were corrected for scatter, decay, randoms, and electronic deadtime. Images were reconstructed using filtered backprojection to a resolution of approximately 12 mm full width at half maximum.

Image analysis {#sec007}
--------------

Image analysis followed routine procedures including normalization for whole-brain activity, intersubject non-linear stereotactic averaging, subtraction of pre- from post-treatment activity, and statistical parametric mapping with regression for age using Neurostat software \[[@pone.0226486.ref076]\]. Parametric maps were overlaid on a template MRI blurred to a similar resolution as the PET scan. In-house software (iiV, <http://james.psych.umn.edu/iiV/>) was used to display results on a standard MRI template \[[@pone.0226486.ref077]\]. To explore individual TRD patient's baseline metabolism, each patient was contrasted with our normative database (N = 30) \[[@pone.0226486.ref063]\]. For the purposes of display, the individually warped *t* images used an uncorrected magnitude threshold of *P* = .05.

Regions of interest {#sec008}
-------------------

Two ROIs were examined based upon existing, extensive literature: amygdala and sgACC (see [Introduction](#sec001){ref-type="sec"} and [Fig 1](#pone.0226486.g001){ref-type="fig"}). The amygdala ROI ([Fig 1A](#pone.0226486.g001){ref-type="fig"}) consisted of a sphere of 13 mm diameter center on each amygdala in the atlas of Talairach and Tournoux at coordinates (±23, -4, -16) \[[@pone.0226486.ref078]\]. Mean counts were collected for each ROI from the pre- and post- treatment scans for each patient. The percent change in MADRS score was regressed linearly against the mean amygdala activity. Paired t-tests were used to compare mean amygdala counts before and after treatment for the group and for responders vs. non-responders separately. A threshold of P \< .05 was used for the ROI analysis.

![Regions of interest.\
**(**A) Amygdala. (B) sgACC/VMPFC.](pone.0226486.g001){#pone.0226486.g001}

Based upon an *a priori* focus on the sgACC, we defined two additional subregions within sgACC for this analysis. Previous studies point to changes in subgenual metabolism that are not restricted to the sgACC of Brodmann area 25 (BA25) but extend along the ventromedial cingulate cortex \[[@pone.0226486.ref010], [@pone.0226486.ref017], [@pone.0226486.ref018], [@pone.0226486.ref040], [@pone.0226486.ref044], [@pone.0226486.ref046], [@pone.0226486.ref079]\]. So, a region including only those voxels labeled as BA25 by the atlas of Talairach and Tournoux \[[@pone.0226486.ref078]\] was created using the Talairach Daemon (<http://ric.uthscsa.edu/projects/talairachdaemon.html>) \[[@pone.0226486.ref080]\]. A second, less specific region was drawn as a cuboid on each hemisphere with the following extents measured from the anterior commissure: x, ±1--12 mm; y, 10--25 mm; z, -5 to -16 mm \[[@pone.0226486.ref078]\]. This approximated the region of hypometabolism associated with antidepressant treatment reported previously by our laboratory \[[@pone.0226486.ref018]\]. The region encompasses BA25, as well as portions of BA32 and BA33 and will be referred to as subgenual/VMPFC ([Fig 1B](#pone.0226486.g001){ref-type="fig"}).

One additional unplanned ROI was included post hoc because of its proximity to the amygdala, involvement in depression, and similar response to treatment in published work \[[@pone.0226486.ref022]\]. A 13 mm diameter spherical ROI was centered on the hippocampus at the following Talairach coordinates: x, ±27 mm, y, -23 mm; z, -9 mm or MNI (±27, -22, -0) <http://sprout022.sprout.yale.edu/mni2tal/mni2tal.html>.

Statistical analyses {#sec009}
--------------------

Clinical changes before and after treatment were assessed with paired *t*-tests. First for image analysis, whole-brain voxel-wise changes in metabolism were measured with statistical parametric mapping using Neurostat software with a statistical threshold of Z = 3.3 as described previously to account for multiple testing \[[@pone.0226486.ref081]\]. Second, mean counts from each ROI were described pre- and post- treatment for responders and non-responders using paired *t*-tests. Percent-change in mean ROI metabolism was linearly regressed against percent-change in MADRS across all subjects. Third, a repeated measures ANOVA was performed on the amygdala, VMPFC, and head of the hippocampus ROIs as defined above. Extensive prior literature highlights these regions as important in affective illness. The BA25 region was not included as no change in activity occurred with treatment (see below). The dependent measure was glucose uptake (PET counts). Repeated measures included TIME (Pre-treatment, Post- treatment), ROI (amygdala, hippocampus, and VMPFC), and SIDE (right hemisphere, left hemisphere). Fourth, the correlation matrix for glucose uptake across amygdala, VMPFC, and hippocampus was calculated for exploratory purposes only ([S2 Table](#pone.0226486.s008){ref-type="supplementary-material"}).

Results {#sec010}
=======

Clinical response {#sec011}
-----------------

Of the 25 enrolled subjects, 16 were withdrawn because of failure to meet inclusion/exclusion criteria on further investigation or inability to complete the full study. Drug wash out led frequently to increased insomnia, anxiety, and depression. Six specific reasons that arose for a consensus by both patient and clinician to terminate included the following: adverse event probably related to olanzapine (lower extremity edema); adverse event probably related to olanzapine (severe sedation); spontaneous remission during washout with patient deciding to not restart medications; severe hyperlipidemia that could be aggravated by olanzapine; lack of any response with patient deciding to discontinue trial; and severe back discomfort during first PET scan related to previous musculoskeletal injury. Side effects from O/F observed reflected those commonly seen with this drug combination \[[@pone.0226486.ref049]\]. There were no suicide attempts during the study. Nine participants completed the entire protocol (clinical MRI; drug washout; O/F treatment; Pre- and Post-treatment PET scans). Clinical data for completers are shown in [Table 1](#pone.0226486.t001){ref-type="table"} which includes demographics, gender, family history of depression, illness onset, comorbidities (both current and lifetime), failed treatments, and response designation. The HAMA and MADRS scores as well as weights before and after treatment are displayed in [S1 Table](#pone.0226486.s007){ref-type="supplementary-material"} and [S1 Data](#pone.0226486.s009){ref-type="supplementary-material"}. The average tolerated dose was 39 mg (range 30--45 mg) of fluoxetine and 12 mg (range 10--12 mg) of olanzapine. Their weight increased significantly during treatment ([S1 Table](#pone.0226486.s007){ref-type="supplementary-material"}; [S1 Fig](#pone.0226486.s001){ref-type="supplementary-material"}); there was no interaction between time (pre vs post) and response (*P* = .20). The average baseline MADRS score was 31 (SD 5; range 24--38); no significant differences arose in baseline MADRS score between responders vs. non-responders (*P* = .63; not shown). Completers showed a decrease in MADRS score following eight weeks of treatment (Mean, 12; SD, 5; [S1 Table](#pone.0226486.s007){ref-type="supplementary-material"}). The baseline HAMA did not differ between responders vs. non-responders (*P* = .72). The HAMA declined significantly also after treatment (*t*(8) = 4.7; *P* = .002) with the significance driven by the non-responders (*P* = .006; responders, *P* = .13). Four patients responded; one of these remitted. Of note, responders tended to have fewer comorbidities and earlier onset than non-responders.

10.1371/journal.pone.0226486.t001

###### Patient demographics and outcomes.

![](pone.0226486.t001){#pone.0226486.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age\           Sex   Family History of MDD   Life time Comorbidity   Current Comorbidity                         Failed medications                                                                                                      Baseline MADRS   \% Change   Response
  ID \#                                                                                                                                                                                                                                                                 
  -------------- ----- ----------------------- ----------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ---------------- ----------- ------------
  47\            F     \+                                              OCD, Anorexia, PD, Anxiety NOS, Dysthymia   SSRIs, venlafaxine, atypical neuroleptics, TCAs, mirtazapine, nefazodone, buproprion, ECT, anticonvulsants, buspirone   33               -6%         \-
  pL0009\                                                                                                                                                                                                                                                               
  pL0011                                                                                                                                                                                                                                                                

  44\            M     \+                                              PD, Dysthymia                               SSRIs, venlafaxine, mirtazapine, benzodiazepines                                                                        29               -17%        \-
  pL0020\                                                                                                                                                                                                                                                               
  pL0021                                                                                                                                                                                                                                                                

  52\            M     unknown                                                                                     SSRIs, venlafaxine, lithium                                                                                             37               -22%        \-
  pL0025\                                                                                                                                                                                                                                                               
  pL0027                                                                                                                                                                                                                                                                

  36\            M     \+                      OCD, ADD                                                            SSRIs, venlafaxine, TCA, MAOI, T3, stimulants, dopamine agonist, anticonvulsants                                        27               -26%        \-
  pL0028\                                                                                                                                                                                                                                                               
  pL0029                                                                                                                                                                                                                                                                

  62\            F     \+                                                                                          SSRIs, venlafaxine, anticonvulsant, atypical neuroleptic                                                                29               -59%        \+
  pL0030\                                                                                                                                                                                                                                                               
  pL0031                                                                                                                                                                                                                                                                

  54\            M     \+                                                                                          SSRIs, venlafaxine, lithium, buspirone, TCA, anticonvulsants                                                            24               -83%        \+\
  pL0059pL0069                                                                                                                                                                                                                                                          (remitted)

  61\            M     \+                      OCD, ADD, dysthymia                                                 SSRIs, venlafaxine, buproprion, benzodiazepine, stimulants, T4, nefazodone                                              31               -35%        \-
  pL0071\                                                                                                                                                                                                                                                               
  pL0072                                                                                                                                                                                                                                                                

  27\            M     \+                      ADHD                    GAD                                         SSRIs venlafaxine, atypical neuroleptic, mirtazapine                                                                    38               -50%        \+
  pL0079pL0087                                                                                                                                                                                                                                                          

  41\            M     \+                                                                                          SSRIs, venlafaxine, atypical neuroleptic                                                                                28               -64%        \+
  pL0089\                                                                                                                                                                                                                                                               
  pL0095                                                                                                                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

M, male; F, female; MDD, major depressive disorder, OCD, obsessive compulsive disorder; ADD, attention deficit disorder; ADHD, attention deficit disorder with hyperactivity; PD, personality disorder; NOS, not otherwise specified; GAD, generalized anxiety disorder; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; ECT, electroconvulsive therapy; MAOI, monoamine oxidase inhibitor; T3, liothyronine;T4, levothyroxine; MADRS, Montgomery Asberg Depression Rating Scale

A 2 x 2 ANOVA with Treatment-response (responder vs. non-responder) as the between-subject factor and Time (post vs. pre-test) as the within-subject factor demonstrated a main effect of Time (*F*(1,7) = 195.2, *P* \< .001), confirming that MADRS scores decreased significantly across sessions ([Fig 2A](#pone.0226486.g002){ref-type="fig"}). The interaction of Treatment-response X Time was also significant (*F*(1,7) = 43.9 *P* \< .001). This interaction confirmed that responders showed significantly greater reductions in MADRS scores than non-responders.

![Changes in depression ratings and regional glucose uptake before and after treatment.\
**(**A) Individual MADRS scores of the responders and non-responders before and after treatment. (N = 9). Non-Responders, red circle; responders, black circle. X denotes group means. (B) Right amygdala metabolism in the brain of responders following olanzapine/fluoxetine treatment was the only significant decrease in the whole-brain voxelwise analysis. Upper left section, coronal; lower section, transverse; upper right section, sagittal.](pone.0226486.g002){#pone.0226486.g002}

Whole-brain exploratory image analysis {#sec012}
--------------------------------------

Voxel-wise comparisons of patients' post- and pre-treatment scans revealed significant changes ([Table 2](#pone.0226486.t002){ref-type="table"}; [S2](#pone.0226486.s002){ref-type="supplementary-material"}--[S4](#pone.0226486.s004){ref-type="supplementary-material"} Figs). Patients were grouped as responders and non-responders (see above) to identify metabolic change associated with successful treatment.

10.1371/journal.pone.0226486.t002

###### Significant changes in whole-brain voxelwise analysis.

![](pone.0226486.t002){#pone.0226486.t002g}

  X (mm)                 Y (mm)   Z (mm)   *Z*-score   Region
  ---------------------- -------- -------- ----------- -------------------------------------
  ***All patients***                                   
  12                     -35      54       +3.4        R paracentral lobule
  6                      -60      43       +3.3        R precuneus (BA7)
  -12                    -60      -20      -4.6        L Cerebellum
  17                     -94      -4       -3.7        R Lingual Gyrus (BA18)
  28                     14       -20      -3.6        R Inferior Frontal Gyrus (BA47)
  -15                    -33      7        -3.6        L Thalamus
  -37                    -64      -22      -3.5        L Cerebellum
  30                     -49      -27      -3.4        R Cerebellum
  -12                    -10      0        -3.4        L Thalamus
  10                     -1       -4       -3.3        R globus pallidus
  ***Non-responders***                                 
  -8                     -60      -16      -5.2        L Cerebellum
  8                      -49      -29      -4.6        R Cerebellum
  -17                    -53      29       -4.4        L Cingulate Gyrus (BA31)
  -44                    32       7        -3.9        L Inferior Frontal Gyrus (BA45)
  -10                    -10      2        -3.9        L Thalamus
  17                     -91      -2       -3.7        R Lingual Gyrus (BA17)
  -51                    -67      14       -3.7        L Middle Temporal Gyrus (BA39)
  -21                    -73      -18      -3.7        L Cerebellum
  1                      -19      -16      -3.4        R Midbrain
  -42                    -4       38       -3.4        L Precentral Gyrus (BA6)
  ***Responders***                                     
  -48                    -13      2        +3.5        Left Superior Temporal Gyrus (BA22)
  -53                    -24      18       +3.4        Left Post-Central Gyrus (BA40)
  6                      -49      36       +3.3        Right Precuneus (BA31)
  10                     -58      38       +3.3        Right Precuneus (BA7)
  19                     -1       -7       -4.4        Right Dorsal Amygdala

R, right; L, left; BA, Brodmann area

Responders showed increases in the left superior temporal and post-central gyri and right precuneus. Significantly reduced metabolism was confined to a peak in the right amygdaloid complex (see [Fig 2B](#pone.0226486.g002){ref-type="fig"}). Of note, liberalizing the threshold to *P* = .05 (uncorrected) revealed bilateral amygdala deactivations. Non-responders showed no significant increases in metabolism following treatment. Areas of reduced metabolism after treatment were found in non-responders in the bilateral cerebellum, lingual gyrus, middle temporal gyrus, thalamus, midbrain, and dorsal cingulate gyrus (see [Table 2](#pone.0226486.t002){ref-type="table"}). For all patients as a group, no significant changes occurred in limbic structures in the whole-brain image analysis.

No studies have reported on individual metabolic patterns associated with unmedicated TRD. To explore this variability while accepting the limitation of the risk for false positive or negative responses, each TRD subject's baseline warped FDG PET (i.e., after medication washout or baseline) was contrasted with those of a normative database with threshold set at *t* = 2.0 for visualization as performed previously \[[@pone.0226486.ref063]\]. These individual subtractions for the nine completers are shown in [S5 Fig](#pone.0226486.s005){ref-type="supplementary-material"} including both increases and decreases in metabolism. Examination of individual subject's scans showed considerable heterogeneity in baseline scans with a mixture of positive, negative, or null changes in the BA25/VMPFC region. This variability suggests baseline heterogeneity in TRD or metabolic changes related to the previous history of failed treatments for TRD. If any antidepressant response occurred, a relationship to metabolic signature was not evident.

Region of interest analyses {#sec013}
---------------------------

### ANOVA on amygdala, hippocampus, and VMPFC {#sec014}

The repeated measures ANOVA indicated significant main effects of TIME (*F*(1,8) = 5.992, *P* = .04) and ROI (*F*(2,16) = 24.94, *P* = .001) without significant interaction effects ([S6 Fig](#pone.0226486.s006){ref-type="supplementary-material"}; [S2 Data](#pone.0226486.s010){ref-type="supplementary-material"}). This result indicates that O/F reduces activity in all three ROIs. To explore potentially interesting relationships given the large number of comparisons, the analysis of the correlation matrix for the ROIs reached significance only for the correlation between the left and right sgACC post-treatment (*r* = .82, *P* = .007; [S2 Table](#pone.0226486.s008){ref-type="supplementary-material"}). O/F tended to increase each region's inter-hemispheric functional connectivity compared to baseline.

### Amygdala region {#sec015}

Responders showed a significant reduction in mean glucose metabolism in the right amygdala ROI (*t*(3) = 3.38, *P* = .04), while non-responders showed no change with treatment (*t*(4) = -0.68, *P* = .54) ([Fig 3A](#pone.0226486.g003){ref-type="fig"}). There was no change in left amygdala metabolism in either group (responders: *t*(3) = 0.88, *P* = .45; non-responders: *t*(4) = 1.29, *P* = .28) ([Fig 3A](#pone.0226486.g003){ref-type="fig"}). Regression analyses showed no correlation between percent reduction in left amygdala metabolism and percent-reduction in MADRS scores across all subjects ([Fig 3B](#pone.0226486.g003){ref-type="fig"}, *r* = -.20, *P* = .61). This correlation was significant in the right amygdala ([Fig 3B](#pone.0226486.g003){ref-type="fig"}, *r* = -.70, *P* = .036). Because the hippocampus is near the amygdala and the resolution of PET in this study is low, the post hoc hippocampal region was also examined for changes in activity.

![Changes in amygdala glucose uptake before and after treatment and its relationship to depression symptoms.\
(A) Amygdala metabolism examined separately for responders vs. non-responders in the right and left amygdala before and after treatment. Blue denotes pretreatment; red denotes post-treatment. (B) Correlation between percentage change in MADRS scores and change in amygdala metabolism. Only the right amygdala showed a significant correlation between change in metabolism and change in MADRS scores. Red line identifies threshold for response.](pone.0226486.g003){#pone.0226486.g003}

### Exploratory subgenual regions (BA 25 & sgACC/VMPFC) {#sec016}

Paired *t*-tests revealed no changes with treatment in either the left or right BA25 metabolism in either responders (left: *t*(3) = 0.05, *P* = .97; right: *t*(3) = 0.71, *P* = .53) or non-responders (left: *t*(4) = 1.13, *P* = .32; right: *t*(4) = 0.67, *P* = .54). Changes in left or right BA25 metabolism showed no correlation with changes from baseline MADRS (left: *r* = .29, *P* = .45; right: *r* = .15, *P* = .69). However, baseline right hemisphere BA25 metabolism showed a marginally significant correlation with change from baseline MADRS, whereby higher baseline metabolism predicted better response to O/F therapy (*r* = 0.68, *P* = .05). This correlation was not significant in the left hemisphere (*r* = 0.13, *P* = .74).

Paired t-tests revealed a significant decrease in right but not left VMPFC metabolism in responders (left: *t*(3) = 0.07, *P* = .95; right: *t*(3) = 4.18, *P* = .02), and no significant change in VMPFC metabolism in non-responders (left: *t*(4) = 0.81, *P* = .47; right: *t*(4) = 0.53, *P* = .62). Changes in VMPFC metabolism showed no correlation with change in MADRS (left: *r* = .11; *P* = .77; right: *r* = .18, *P* = .64). Baseline metabolism in the right, but not left, VMPFC area correlated with MADRS reduction, with higher baseline metabolism predicting better response (left: *r* = 0.37, *P* = .33; right: *r* = .84, *P* = .018).

Discussion {#sec017}
==========

This preliminary study found that medication-free TRD patients treated with O/F at therapeutic doses for an adequate duration showed a response-related decline in the metabolism of the right dorsal amygdala using a whole-brain, voxel-wise analysis. The dorsal amygdala in humans consists mostly of the central nucleus, the terminus of the spino-parabrachial-amygdaloid pain pathway and the principal efferent pathway for the emotional and physiological processing. Given the low resolution of the present study, caution is warranted in localization pending higher resolution techniques (e.g., higher resolution PET scanners and coregistered high resolution MRI). Several increases in metabolism surfaced also after treatment.

Two regions of interest (and one post-hoc region) based on existing literature were examined for drug-related changes in metabolism and relationship to response (see citations in Introduction). Following treatment, the change in metabolism of the right amygdala correlated with the change in MADRS score; no correlation was observed for the left amygdala. Treatment did not significantly change the smaller sgACC region defined as BA25. However, a broader ROI along the VMPFC approached significance despite the small sample size.

ANOVA of ROIs in the VMPFC, amygdala, and immediately adjacent hippocampus (a post hoc exploratory ROI) indicated a main effect of treatment and ROI without significant interactions. The VMPFC showed the highest activity. O/F was associated with reduced activity in all ROIs tested. The hippocampus did not appear responsible for the deactivation seen in the dorsal amygdala. However, the hippocampus may have followed similar changes with treatment that did not reach significance; such changes have been reported previously \[[@pone.0226486.ref022], [@pone.0226486.ref044]\].

Baseline metabolism in TRD may have relevance to treatment response and may, if confirmed, find utility for patient selection in treatment trials. Greater baseline metabolism in right BA25 and sgACC/VMPFC predicted better response to O/F therapy. Also, responders showed a significant decrease in metabolism following treatment in the right VMPC region which could reflect a higher initial baseline (as BA25 was included in the right VMPFC region). The higher baseline BA25 metabolism in responders to O/F may relate to 1) higher baseline resting sgACC/VMFPC blood flow seen in TRD patients when compared to controls during neuromodulation trials \[[@pone.0226486.ref010], [@pone.0226486.ref011]\]; 2) increased sgACC blood flow induced by sadness induction \[[@pone.0226486.ref082]\]; and 3) and increased resting blood flow in sgACC/VMFPC in healthy subjects high in negative affect \[[@pone.0226486.ref047]\]. Likewise, the decline in right VMPFC activity in TRD treated with O/F is analogous to the decline in resting blood flow in VMPFC in TRD responders treated with deep brain stimulation \[[@pone.0226486.ref010]\] as well as decreased VMPFC metabolism with chronic vagus nerve stimulation \[[@pone.0226486.ref017], [@pone.0226486.ref018]\].

Strengths of the study include the recruitment of severely ill TRD patients, medication washout before treatment, exploratory examination of individual TRD patients, and full course of treatment with O/F to maximal tolerated doses. These preliminary data suggest heterogeneity in metabolic signatures in TRD. If replicated, this heterogeneity requires consideration in the design of trials for TRD using medications or devices. However, the changes observed with treatment appear broadly like those reported in treatment-responsive major depression with other antidepressant treatments: decreased amygdala and VMPFC metabolism.

Limitations of this study include comorbidities, prior heterogeneous treatments during past failed trials, significant participant dropout, small final sample size, lack of a placebo, low PET resolution, multiple testing with potential for alpha error inflation, and confounding of depression with anxiety measures. Patient dropouts and comorbidities could limit generalizability. However, the whole brain analysis used a conservative threshold to address the large number of voxels in the brain, and the amygdala finding converges with the literature making a spurious finding unlikely. Most TRD patients do have comorbidity \[[@pone.0226486.ref005]--[@pone.0226486.ref008]\]. A larger replication sample could address whether major comorbidities represent a covariate of interest in the response as suggested by this study---likewise for dropouts. Future studies will need to account for the dropout during washout. The limited resolution of PET places some ambiguity in the precise determination of amygdala activity. However, the latest scanners with resolution of 3 mm full width at half maximum will improve localization in future studies. Of note, although the ROI analysis of the right amygdala confirmed significant deactivation after treatment that correlated with clinical response, the focus was only partially resolved from other nearby regions which showed a similar response pattern (e.g., hippocampus). Depression and anxiety are both prominent symptoms in TRD, and antidepressants/atypical neuroleptics often decrease both depression and anxiety scores. In this regard, HAMD and HAMA scores are inter-correlated \[[@pone.0226486.ref083]\]. Anxiety scores measured in this study in responders before and after treatments did not differ. Therefore, the decrease in amygdala activity does not likely reflect changes in anxiety, but rather depression. The severity of illness and risk of suicide precluded a placebo control. However, other studies using FDG PET and placebos in test-retest designs suggest high consistency in normalized regional activity and only small changes \[[@pone.0226486.ref084]--[@pone.0226486.ref086]\].

Conclusions {#sec018}
===========

TRD patients show considerable baseline metabolic heterogeneity following medication washout. Whether this heterogeneity arises from differing disease pathologies or from effects of past treatments remains unclear. As reported for other antidepressant therapies in treatment-responsive depression, decline in amygdala and VMPFC activity surfaced here with O/F treatment. Furthermore, decreased metabolism in the right amygdala with treatment correlated with improvement in depression following O/F treatment.

Supporting information {#sec019}
======================

###### Weights before and after O/F combination.

(PDF)
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Click here for additional data file.

###### Brain glucose uptake in non-responders: Post- minus Pre- O/F treatment.

Stereotactically normalized. Image left is right side of brain. AC-PC plane 0 mm. Color scale shows Z-scores with threshold Z = ±3.3.

(PDF)

###### 

Click here for additional data file.

###### Brain glucose uptake in responders: Post- minus Pre- O/F treatment.

Stereotactically normalized. Image left is right side of brain. AC-PC plane 0 mm. Color scale shows Z-scores with threshold at Z = ±3.3.

(PDF)

###### 

Click here for additional data file.

###### Brain glucose uptake for all subjects: Post- minus Pre- O/F treatment.

Stereotactically normalized. Image left is right side of brain. AC-PC plane 0 mm. Color scale shows Z-scores with threshold at Z = ±3.3.

(PDF)
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Click here for additional data file.

###### Differences in resting brain glucose uptake between individual subjects (N = 9) at baseline (after washout) and a normative data set (N = 30).

For visualizing individual metabolic fingerprints of all nine subjects, the threshold was set at *t* = 2.0 that is the usual threshold used for studying change in individuals \[[@pone.0226486.ref042]\]. Each subject is represented by a study number (e.g., pL0009). Age regression was used to match individual subject's age to that of the normative group. R, right; L, left, A, anterior; P, posterior. The patterns are heterogenous. For example, some individuals have sgACC/VMPFC hypoactive, hyperactivity, or no change.

(PDF)
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Click here for additional data file.

###### Main effects of TIME and ROI on glucose uptake.

(PDF)
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Click here for additional data file.

###### Individual subject's weight, depression scores, and anxiety ratings.

(PDF)
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Click here for additional data file.

###### Correlation matrix for metabolism in bilateral ROIs.

Green cells below diagonal are for Pre-treatment; blue cells above diagonal are for Post-treatment. R, right; L, left; Hippo, hippocampus; sgACC, subgenual anterior cingulate/VMPFC. ^†^ *P* = .007

(PDF)
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###### Subject data.
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Click here for additional data file.

###### Regional glucose uptake values.

(PDF)
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Click here for additional data file.
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